nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

06.07.2020 | Original Article – Clinical Oncology

Surgical outcomes of second primary lung cancer after the extrapulmonary malignancy

verfasst von: Kai-Hsiung Ko, Hsu-Kai Huang, Yi-I Chen, Hung Chang, Wu-Chuan Tsai, Tsai-Wang Huang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

To study the surgical outcomes of patients with a second primary lung cancer after the extrapulmonary malignancy.

Materials and methods

Patients who underwent surgical resection for lung cancers between January 2005 and December 2014 were reviewed. Clinical data, imaging characteristics of tumors, surgical approaches, and outcomes were analyzed with a mean follow-up of 97 months.

Results

Of 1075 patients, 166 (15.4%) had a second primary lung cancer after extrapulmonary malignancy. There were no differences in overall 5-year survival rates (81.8% for the group of lung cancer vs. 72.9% for the second primary lung cancer group, p = 0.069) and 5-year disease-free survival (70.1% for the lung cancer group vs. 70.3% for the second primary lung cancer group, p = 0.863) between the two groups. Gender, performance status, tumor size, and maximum standard uptake value (SUVmax) were significantly different between the two groups. After propensity-score matching analysis, patients in the group with lung cancers had better 5-year overall survival (88.1% vs. 72.1% for the group with second primary lung cancers, p = 0.016) and 5-year disease-free survival (80.6% vs. 70.3% for the group with second primary lung cancers; p = 0.054). In the second primary lung cancer group, the patients with preceding breast or thyroid cancers had better prognoses than did those with other extrapulmonary malignancy.

Conclusions

Second primary lung cancers following extrapulmonary malignancies were not uncommon. Surgical resection is considered for early stage secondary primary lung cancer after meticulous work up and result in fair outcome.

Brock MV, Alberg AJ, Hooker CM, Kammer AL, Xu L, Roig CM, Yang SC (2004) Risk of subsequent primary neoplasms developing in lung cancer patients with prior malignancies. J Thorac Cardiovasc Surg 127(4):1119–1125CrossRef

Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA (2005) The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 130:151–159CrossRef

Detterbeck FC, Chansky K, Groome PB et al (2016) Staging I, Prognostic Factors Committee Advisory Board. Participating I The IASLC Lung Cancer Staging Project: methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming (eighth) edition of the TNM classification of lung cancer. J Thorac Oncol. 11:1433–1446CrossRef

Duchateau CS, Stokkel MP (2005) Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival. Chest 127:1152–1158PubMed

Gazdar AF (2009) Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 361(10):1018–1020CrossRef

Griffioen GH, Louie AV, de Bree R, Smit EF, Paul MA, Slotman BJ, Leemans CR, Senan S (2015) Second primary lung cancers following a diagnosis of primary head and neck cancer. Lung Cancer 88(1):94–99CrossRef

Ha D, Choi H, Chevalier C, Zell K, Wang XF, Mazzone PJ (2015) Survival in patients with metachronous second primary lung cancer. Ann Am Thorac Soc 12(1):79–84CrossRef

Hofmann HS, Neef H, Schmidt P (2007) Primary lung cancer and extrapulmonary malignancy. Eur J Cardiothorac Surg 32:653–658CrossRef

Hsu LH, Feng AC, Kao SH, Liu CC, Tsai SY, Shih LS, Chu NM (2015) Second primary lung cancers among breast cancer patients treated with anti-estrogens have a longer cancer-specific survival. Anticancer Res 35(2):1121–1127PubMed

Huang YJ, Huang TW, Lin FH, Chung CH, Tsao CH, Chien WC (2017) Radiation therapy for invasive breast cancer increases the risk of second primary lung cancer: a nationwide population-based cohort analysis. J Thorac Oncol 12(5):782–790CrossRef

Lim MC, Won YJ, Lim J, Salehi T, Yoo CW, Bristow RE (2018) Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study. BMC Cancer 18(1):800CrossRef

Lu MS, Chen MF, Huang YK, Liu HP, Tsai YH (2016) Clinical outcome in lung cancer with a second malignancy: the time sequence matters. Medicine (Baltimore) 95:e5203CrossRef

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388CrossRef

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P et al (2009) Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–995CrossRef

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500CrossRef

Preyer O, Concin N, Obermair A, Concin H, Ulmer H, Oberaigner W (2017) The relative risk of second primary cancers in Austria’s western states: a retrospective cohort study. BMC Cancer. 17(1):699CrossRef

Reinmuth N, Stumpf P, Stumpf A et al (2014) Characteristics of lung cancer after a previous malignancy. Respir Med 108:910–917CrossRef

Rheingold SR, Neugut AI, Meadows AT (2000) Second cancers: incidence, risk factors and management. In: Bast RC, Kufe DW, Pollock RE, et al. (eds) Cancer medicine. B.C. Decker, Hamilton, pp 2399–2406

Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K, American College of Chest Physicians (2007) Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines. Chest 132:234S–242SCrossRef

Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350:379–392CrossRef

Yang X, Zhan C, Li M, Huang Y, Zhao M, Yang X, Lin Z, Shi Y, Jiang W, Wang Q (2018) Lobectomy versus sublobectomy in metachronous second primary lung cancer: a propensity score study. Ann Thorac Surg 106(3):880–887CrossRef

Yendamuri S, Sharma R, Demmy M, Groman A, Hennon M, Dexter E, Nwogu C et al (2013) Temporal trends in outcomes following sublobar and lobar resections for small (≤ 2 cm) non-small cell lung cancers—a Surveillance Epidemiology End Results database analysis. J Surg Res 183(1):27–32CrossRef

Titel: Surgical outcomes of second primary lung cancer after the extrapulmonary malignancy
verfasst von: Kai-Hsiung Ko
Hsu-Kai Huang
Yi-I Chen
Hung Chang
Wu-Chuan Tsai
Tsai-Wang Huang
Publikationsdatum: 06.07.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03310-x

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Surgical outcomes of second primary lung cancer after the extrapulmonary malignancy